You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Imbruvica

Showing 126 - 146 of 146
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Adult Acute Myeloid Leukemia Trial in Palo Alto (Cytarabine, Ibrutinib, Idarubicin)

Terminated
  • Recurrent Adult Acute Myeloid Leukemia
  • Palo Alto, California
    Stanford University, School of Medicine
May 7, 2018

Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Anemia
  • +2 more
  • Birmingham, Alabama
  • +795 more
Jan 28, 2023

Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B Trial in Hong Kong (Ibrutinib)

Unknown status
  • Chronic Lymphocytic Leukemia
  • +6 more
  • Hong Kong, Hong Kong
    The University of Hong Kong
Apr 11, 2018

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Washington (Lenalidomide, Ibrutinib, Rituximab)

Terminated
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Lenalidomide, Ibrutinib, Rituximab
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Jan 10, 2018

Amyloidosis, Immunoglobulin Light Chain Deposition Trial (Bortezomib, Dexamethasone, Ibrutinib)

Withdrawn
  • Amyloidosis
  • Immunoglobulin Light Chain Deposition
  • (no location specified)
Feb 28, 2018

Healthy Trial in Tempe (Ibrutinib, IMBRUVICA)

Completed
  • Healthy
  • Tempe, Arizona
    (unnamed)
Mar 8, 2017

CD20 Positive, Recurrent DLBCL, Refractory DLBCL Trial in New York (drug, other, biological)

Completed
  • CD20 Positive
  • +2 more
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Jan 25, 2018

B-Cell Chronic Lymphocytic Leukemia Trial in Canada, Russian Federation, Spain (Ibrutinib, Erythromycin, Voriconazole)

Completed
  • B-Cell Chronic Lymphocytic Leukemia
  • N/a N/a, Canada
  • +5 more
Jun 23, 2017

Lung Cancer, Nonsmall Cell, Stage I Trial (Ibrutinib, Nivolumab)

Withdrawn
  • Lung Cancer, Nonsmall Cell, Stage I
  • (no location specified)
Feb 10, 2017

Food Allergy, Anaphylaxis Food Trial in Chicago (Ibrutinib)

Completed
  • Food Allergy
  • Anaphylaxis Food
  • Chicago, Illinois
    Ann & Robert H. Lurie Childrens Hospital of Chicago
Nov 14, 2018

GVHD Trial in United States (Ibrutinib)

Completed
Has Results
  • Graft Versus Host Disease
  • Duarte, California
  • +9 more
Jun 14, 2019

Lymphoma, Mantle-cell Trial in Japan (Ibrutinib)

Completed
  • Lymphoma, Mantle-cell
  • Fukuoka, Japan
  • +7 more
Jan 23, 2017

Leukemia, Lymphocytic, Chronic, B-Cell Trial in Toronto (ruxolitinib, ibrutinib)

Unknown status
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Toronto, Ontario, Canada
  • +1 more
Mar 8, 2017

Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma Trial in Ramat

Unknown status
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
  • Ramat Gan, Israel
  • +1 more
Apr 21, 2019

Lymphoma Trial in Worldwide (PCI-32765 (Ibrutinib))

Completed
  • Lymphoma
  • PCI-32765 (Ibrutinib)
  • Los Angeles, California
  • +53 more
Jul 14, 2017

Diffuse Large B Cell Lymphoma, DLBCL Recurrent Trial in Singapore City, Singapore (Ibrutinib-RICE)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma Recurrent
  • Singapore City, Singapore
  • +3 more
Feb 13, 2017

NSCLC, Breast Cancer, Pancreatic Cancer Trial in United States (Ibrutinib, Durvalumab)

Completed
Has Results
  • Non-Small Cell Lung Cancer
  • +2 more
  • Birmingham, Alabama
  • +16 more
Dec 7, 2018

Mantle Cell Lymphoma Trial in Worldwide (R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning)

Recruiting
  • Mantle Cell Lymphoma
  • Aalborg, Denmark
  • +111 more
Dec 17, 2017

Diffuse Large Cell B-lymphoma Trial in United States (ibrutinib)

Completed
Has Results
  • Diffuse Large Cell B-lymphoma
  • Los Angeles, California
  • +14 more
Mar 2, 2017

Lymphoma, B-Cell Trial in Italy (Obinutuzumab, Ibrutinib, CHOP)

Terminated
  • Lymphoma, B-Cell
  • Candiolo, TO, Italy
  • +28 more
Mar 16, 2017

Core: Relapsed or Refractory DLBCL, Module 1: Non-GCB DLBCL Trial (AZD2014, Ibrutinib)

Withdrawn
  • Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  • Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
  • (no location specified)
Sep 14, 2016